Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II for Septic Shock (ANGSTROM)
NCT03302650Phase 3Suspended
- Sponsor
- Cairo University
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Angiotensin II in septic shock (2 arms), sponsored by Cairo University. Primary endpoint: Mean flow index at 6 hours. Started Apr 2019; status: suspended.
02
Drugs
Angiotensin II
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03302650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302650.